IPO round-up: SteadyMed raises less than expected in seventh medtech IPO of 2015
This article was originally published in Clinica
Executive Summary
Israeli firm SteadyMed, which is developing a drug-device combination product for the treatment of pulmonary arterial hypertension (PAH), has priced its IPO – but raised less than expected.